Get all premium features to the best stock analysis tool

Finranks

Finranks

Company

  • About us

Contact us

  • [email protected]

Follow us

  • Instagram
  • Telegram
  • LinkedIn

All rights reserved.

Privacy PolicyTerms of Conditions
  • Home
  • Markets
  • Screener
  • News
  • About
  1. Home
  2. ZNTL
Z

Zentalis Pharmaceuticals, Inc. (ZNTL)

NGM – Real Time Price. Currency in USD

2.10

-0.57 (-21.35%)

At close: Mar 27, 2026, 4:00 PM EDT

2.17

+0.07 (3.33%)

After-hours: Mar 27, 2026, 7:11 PM EDT

  • Summary
  • News
  • Chart
  • Financial
  • Dividends
  • Forecast
  • Ownership
  • Profile

Stock details

Previous close
2.1$
Day's range
2.09 - 2.61$
52-week range
1.01 - 3.95$
Volume
1 145 263
Average volume
498 930
Beta
2.92
EPS (TTM)
-1.91
PE ratio (TTM)
N/A
Market cap
148 955 125
Shares outstanding
70 931 012
Dividend yield
N/A
Next earnings date
2026-05-13
Sector
Healthcare
Industry
Biotechnology

About the company

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumor... read more
CEO
Julie Eastland
Country
United States
IPO Date
2020-04-03
Employees
166
Fiscal Year End
January - December
Website
https://zentalis.com

Revenue Breakdown

Novel Small Molecule Therapeutics / 100.00%

News

No Data

There are no news for this stock.

Chart: ZNTL

Loading Chart...

Overall Score

3.4 / 1034%
Financial Strength
7.6
Profitability
1
Effectiveness
1
Growth
6.4
Forecast
4.4
Valuation
4.5

Financial Strength

NAMERATIOINDUSTRY5Y TRENDSCORE
Current ratio7.766.0510
Quick ratio7.765.6310
Debt to Equity0.160.309.0
Debt to Assets0.121.048.0
Interest coverageN/A-16.911.0
Weighted average score7.6

Debt to Assets

Financial

Values in USD
(B=Billions, M=Millions, K=Thousands)
Values in USD (B=Billions, M=Millions, K=Thousands)
METRIC2021202220232024TTM
Total RevenueN/AN/AN/A67M27M
Gross Profit-544K-1M-1M66M26M
Operating Income-208M-227M-254M-187M-153M
Net Income-159M-237M-292M-166M-149M
EBITDA-207M-226M-253M-186M-152M

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

NAMERATIOINDUSTRY5Y TRENDSCORE
Gross margin %N/A-11.73
1.0
Operating margin %N/A-24.60
1.0
Net margin %N/A-172.20
1.0
EBITDA margin %N/A-201.27
1.0
Cash flow margin %N/A-156.39
1.0
Weighted average score1.0

Net Margin

Effectiveness

NAMERATIOINDUSTRY5Y TRENDSCORE
ROA-39.51-57.97
1.0
ROE-50.25-63.56
1.0
ROIC-45.06-42.57
1.0
ROCE-11.58-71.10
1.0
Weighted average score1.0

Estimated EPS vs Actual EPS

Forecast

NAMEREVENUE GROWTHEPS GROWTHSCORE
Current quarter-10036.325.5
Next quarterN/A30.285.5
Current year-10021.735.5
Next yearN/A-2.091.0
Weighted average score4.4

Analyst Rating

Growth

NAMEREVENUENET INCOMEEPSFCFSCORE
Q/Q9990.68022.315.8
Y/Y99933.5433.9338.7810
3y average999-9.769.22-3.724.5
5y average999-44.417.55-43.165.3
Weighted average score6.4

Revenue Growth Rate vs. Industry

Valuation

NAMERATIOINDUSTRY5Q TRENDSCORE
P/EN/A-5.25
1.0
PEG (5yr expected)N/A0.27
1.0
P/S6.9764.66
6.4
P/B0.672.96
9.4
Weighted average score4.5

DCF Model

DCF Model PeriodN/A
Discount rateN/A
Perpetual growth rateN/A
Revenue 5 year CAGRN/A
FCF 5 year CAGRN/A
Fair value$
Stock price2.1$

Dividend

NAMECURRENTINDUSTRYSCORE
Dividend yield0.00N/A1.0
Payout ratio0.00N/A1.0
5-year dividend growth rateN/AN/A1.0
Years of dividend increaseN/AN/A1.0
Weighted average score1.0

Fair Value

Fair Value

$1

UndervaluedStock priceOvervalued

$2.1

Economic Moat

NAMESCALESCORE
Market shareNone1.0
Intangible assetsNone1.0
Switching costsNone1.0
Network effectNone1.0
Economies of scaleNone1.0
Weighted average score1.0
Dividend
1
Economic Moat
1

Octagon View

Strength & Weakness

Cash reserves $39.1M barely cover the upcoming debt maturities $40.5M

Total current assets $288.3M exceed Total current liabilities $37.2M, highlighting excellent liquidity

Debt-to-equity ratio (0.2) is well below the industry average (0.3), showcasing prudent financial management

Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns

Negative free cash flow -$27.0M limits the company's ability to reinvest or pay down debt